Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityPTI / Proteostasis Therapeutics, Inc. (74373B109)
President and CEOChhabra Meenu
IndustryPharmaceutical Preparations
Institutional Owners57
Institutional Shares24,628,297 - 68.26%
Common Shares Outstanding36,081,032 shares (as of 2018-03-31)
Institutional Value$ 119,388,000 USD

Institutional Stock Ownership and Shareholders()

PTI / Proteostasis Therapeutics, Inc. Institutional Ownership

Proteostasis Therapeutics, Inc. (NASDAQ:PTI) has 57 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24,628,297 shares. Largest shareholders include NEA Management Company, LLC, Wellington Management Group LLP, Jennison Associates Llc, Rtw Investments, Llc, Vanguard Group Inc, Hillhouse Capital Management, Ltd., FMR LLC / Fidelity, Price T Rowe Associates Inc /md/, Rock Springs Capital Management LP, and FIL Ltd.
Proteostasis Therapeutics, Inc. (NASDAQ:PTI) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/pti"><img src="https://images.fintel.io/us-pti-so.png" alt="PTI / Proteostasis Therapeutics, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-05-15 13F-HR J. Goldman & Co LP 550,043 0 -100.00 3,207 0 -100.00
2018-04-17 13F-HR Calton & Associates, Inc. 2,000 0 -100.00 8 0 -100.00
2018-05-07 13F-HR BAILARD, INC. 520,100 2,470
2018-05-16 13F-HR DOHENY ASSET MANAGEMENT /CA 69,625 331
2018-05-11 13F-HR Tibra Equities Europe Ltd 52,987 252
2018-05-14 13F-HR GRANAHAN INVESTMENT MANAGEMENT INC/MA 70,534 335
2018-05-11 13F-HR Cutler Group LP Call 14,600 3
2018-05-15 13F-HR JANE STREET GROUP, LLC 34,797 0 -100.00 203 0 -100.00
2018-05-15 13F-HR Moore Capital Management, LP 100,000 0 -100.00 583 0 -100.00
2018-05-15 13F-HR TUDOR INVESTMENT CORP ET AL 25,000 0 -100.00 146 0 -100.00
2018-05-15 13F-HR Hillhouse Capital Management, Ltd. 865,923 865,923 0.00 5,048 4,113 -18.52
2018-05-15 13F-HR SECTORAL ASSET MANAGEMENT INC 300,000 0 -100.00 1,749 0 -100.00
2018-05-02 13F-HR WELLS FARGO & COMPANY/MN 6,000 6,000 0.00 35 29 -17.14
2018-05-15 13F-HR BlueCrest Capital Management Ltd 77,572 368
2018-05-11 13F-HR MACQUARIE GROUP LTD 1,500 0 -100.00 9 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 810 4,045 399.38 5 19 280.00
2018-05-10 13F-HR FRANKLIN RESOURCES INC 243,400 110,400 -54.64 1,419 524 -63.07
2018-05-15 13F-HR Endurant Capital Management LP 485,012 472,012 -2.68 2,828 2,242 -20.72
2018-05-14 13F-HR FIL Ltd 652,316 652,316 0.00 3,803 3,099 -18.51
2018-05-14 13F-HR Bayesian Capital Management, LP 33,500 159
2018-05-15 13F-HR DEUTSCHE BANK AG\ 20 20 0.00 0 0
2018-05-14 13F-HR UBS OCONNOR LLC 118,000 0 -100.00 688,000 0 -100.00
2018-05-11 13F-HR Cutler Group LP 2,000 9
2018-05-15 13F-HR MILLENNIUM MANAGEMENT LLC 953,513 212,891 -77.67 5,559 1,011 -81.81
2018-05-07 13F-HR SCHWAB CHARLES INVESTMENT MANAGEMENT INC 18,300 18,300 0.00 107 87 -18.69
2018-05-15 13F-HR Rock Springs Capital Management LP 675,000 675,000 0.00 3,935 3,206 -18.53
2018-05-15 13F-HR HARBOURVEST PARTNERS LLC 440,627 440,627 0.00 2,569 2,093 -18.53
2018-05-03 13F-HR MEEDER ASSET MANAGEMENT INC 932 451 -51.61 5 2 -60.00
2018-05-15 13F-HR STATE STREET CORP 0 13,400 0 63
2018-05-15 13F-HR Jefferies Group LLC 30,000 0 -100.00 175 0 -100.00
2018-07-17 13F-HR ESSEX INVESTMENT MANAGEMENT CO LLC 96,900 96,900 0.00 460 270 -41.30
2018-05-15 13F-HR Bank of New York Mellon Corp 10,946 17,666 61.39 64 84 31.25
2018-05-15 13F-HR VANGUARD GROUP INC 324,571 950,327 192.79 1,892 4,514 138.58
2018-05-11 13F-HR TD ASSET MANAGEMENT INC 0 21,200 0 101
2018-05-15 13F-HR ELEMENT CAPITAL MANAGEMENT LLC 0 33,360 0 158
2018-05-15 13F-HR BALYASNY ASSET MANAGEMENT LLC 657,500 0 -100.00 3,833 0 -100.00
2018-05-15 13F-HR BROOKSIDE CAPITAL MANAGEMENT LLC 828,916 399,947 -51.75 4,833 1,900 -60.69
2018-05-15 13F-HR BRIDGEWAY CAPITAL MANAGEMENT INC 139,500 138,845 -0.47 813 660 -18.82
2018-05-15 13F-HR LORD, ABBETT & CO. LLC 481,093 2,285
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 41,200 41,200 0.00 240 196 -18.33
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Put 180,400 857
2018-05-07 13F-HR MUFG Americas Holdings Corp 615 0 -100.00 4 0 -100.00
2018-05-11 13F-HR Cutler Group LP Put 10,200 34
2018-05-15 13F-HR CREDIT SUISSE AG/ 0 16,961 0 81
2018-05-14 13F-HR FMR LLC / Fidelity 857,500 800,967 -6.59 4,999 3,805 -23.88
2017-02-10 13F-HR BlackRock Japan Co. Ltd 201 0 -100.00 3 0 -100.00
2018-05-15 13F-HR Alyeska Investment Group, L.P. 100,000 79,945 -20.05 583 380 -34.82
2018-05-15 13F-HR GEODE CAPITAL MANAGEMENT, LLC 69,976 168,141 140.28 407 798 96.07
2018-05-09 13F-HR NORTHERN TRUST CORP 23,618 43,034 82.21 138 204 47.83
2018-05-15 13F-HR Marshall Wace North America L.P. 118,492 0 -100.00 691 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 500 10,550 2,010.00 3 50 1,566.67
2017-02-10 13F-HR BlackRock Fund Advisors 215,224 253,809 17.93 3,355 3,112 -7.24
2018-05-10 13F-HR NEA Management Company, LLC 5,556,778 5,556,778 0.00 32,396 26,395 -18.52
2018-05-15 13F-HR Squarepoint Ops LLC 46,718 0 -100.00 272 0 -100.00
2018-04-20 13F-HR JENNISON ASSOCIATES LLC 3,178,432 3,621,854 13.95 18,530 17,204 -7.16
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP Call 220,100 1,045
2018-05-15 13F-HR TWO SIGMA INVESTMENTS LLC 0 62,223 0 296
2017-02-10 13F-HR BlackRock Institutional Trust Company, N.A. 52,807 55,270 4.66 823 678 -17.62
2018-05-03 13F-HR Trexquant Investment LP 0 31,296 0 149
2018-05-14 13F-HR MORGAN STANLEY 35,154 25,966 -26.14 205 123 -40.00
2018-07-13 13F-HR BANK OF MONTREAL /CAN/ 179 0
2018-05-15 13F-HR Schonfeld Strategic Advisors LLC 162,154 0 -100.00 946 0 -100.00
2018-05-15 13F-HR Cormorant Asset Management, LLC 3,300,000 0 -100.00 19,239 0 -100.00
2018-05-15 13F-HR Wellington Management Group LLP 4,827,560 22,931
2018-05-15 13F-HR MANUFACTURERS LIFE INSURANCE COMPANY, THE 0 1,327 0 6
2018-05-15 13F-HR LADENBURG THALMANN FINANCIAL SERVICES INC 6,200 0 -100.00 36 0 -100.00
2018-05-15 13F-HR BARCLAYS PLC 2,201 54,957 2,396.91 12 261 2,075.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 0 20,682 0 98
2018-05-15 13F-HR DAFNA Capital Management LLC 117,500 267,100 127.32 685 1,269 85.26
2018-05-09 13F-HR BlackRock Inc. 42,061 47,654 13.30 245 226 -7.76
2018-05-15 13F-HR/A Sabby Management, LLC 60,000 0 -100.00 350 0 -100.00
2018-05-15 13F-HR Tower Research Capital LLC (TRC) 22,221 0 -100.00 130 0 -100.00
2018-05-10 13F-HR JP Morgan Chase & Co 212,643 212,493 -0.07 1,240 1,009 -18.63
2018-05-15 13F-HR UBS Group AG 86 2,504 2,811.63 1 12 1,100.00
2018-05-15 13F-HR Omega Advisors Inc. 150,000 0 -100.00 875 0 -100.00
2018-05-14 13F-HR RTW INVESTMENTS, LLC 1,500,000 1,104,940 -26.34 8,745 5,248 -39.99
2018-05-15 13F-HR GOLDMAN SACHS GROUP INC 60,796 41,468 -31.79 354 197 -44.35
2017-02-10 13F-HR BlackRock Investment Management, LLC 32,586 33,673 3.34 508 413 -18.70
2018-05-14 13F-HR PRICE T ROWE ASSOCIATES INC /MD/ 158,924 768,804 383.76 927 3,652 293.96
2018-05-11 13F-HR DIMENSIONAL FUND ADVISORS LP 48,531 37,027 -23.70 283 176 -37.81
2017-02-10 13F-HR BlackRock Advisors LLC 2,894 2,894 0.00 45 35 -22.22

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Vertex Hits The Top, As Competitor Galapagos Doesn't Impress In Cystic Fibrosis Study

2018-07-02 seekingalpha
Vertex Pharmaceuticals' stock traded higher by 14% after Galpago's phase 2 cystic fibrosis study didn't impress. (16-0)

Your Daily Pharma Scoop: Scynexis Moves Up, Proteostasis Disappoints Investors, Cellectar Zooms

2018-06-11 seekingalpha
Scynexis (NASDAQ:SCYX) is a drug manufacturer focusing on infectious diseases and has $83.85M in market capitalization. The company’s lead candidate SCY-078 is on trial for treatment of multiple serious fungal infections. Some of these fungal infections like Acute Vulvovaginal Candidiasis, Invasive Candidiasis and Invasive Aspergillosis Combo are difficult to treat and can turn into life-threatening conditions. (89-2)

Proteostasis Therapeutics (PTI) Enters Oversold Territory

2018-06-08 zacks
Proteostasis Therapeutics, Inc. (PTI - Free Report) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock. And for technical investors, there is some hope when looking at PTI given that, according to its RSI reading of 22.71, it is now in oversold territory. (125-2)

Proteostasis Falls On Phase 1 Data, But Was Greatly Misunderstood

2018-06-08 seekingalpha
Proteostasis Therapeutics tumbles on release of phase 1 data, but I believe that the results were misunderstood. (16-1)

CUSIP: 74373B109